WebGreenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer … Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical … GP2 immunotherapy trains a patient’s T cells to recognize and destroy … The current, ongoing trial is a Phase III clinical trial registered with the name, … Greenwich LifeSciences, Inc. 3992 Bluebonnet Drive Building 14 Stafford, … about. management team; board of directors; technology. our gp2 cancer … The Greenwich LifeSciences’ leadership is dedicated to discovering and developing … GP2 is a nine amino acid transmembrane peptide of the HER2/neu protein. … Understand cancer and immunotherapy, cancer’s escape from … Greenwich LifeSciences Provides Year End Update. Dec 1, 2024 6:00am EST. … Company Info - Greenwich LifeSciences, Inc. (GLSI) GP2 WebApr 14, 2024 · Shares of Greenwich LifeSciences stock opened at $11.97 on Friday. The company has a market capitalization of $153.81 million, a price-to-earnings ratio of -21.00 and a beta of 0.93. Greenwich ...
GLSI Insider Trading Greenwich LifeSciences Buys and Sells
WebDec 1, 2024 · Investor & Public Relations Contact for Greenwich LifeSciences Dave Gentry RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447) Cell: (407) 491-4498 Email: [email protected]. WebApr 14, 2024 · Greenwich LifeSciences, Inc. ( NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, April … pasta filmora9
Greenwich LifeSciences Extends Lock-up of Directors and …
WebApr 12, 2024 · Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) had its price objective reduced by stock analysts at HC Wainwright from $78.00 to $38.00 in a research report issued to clients and investors on Monday, The Fly reports. ... Walleye Capital LLC bought a new stake in shares of Greenwich LifeSciences in the second quarter worth … WebApr 12, 2024 · Greenwich LifeSciences ( NASDAQ:GLSI – Get Rating) had its price objective reduced by stock analysts at HC Wainwright from $78.00 to $38.00 in a … WebApr 10, 2024 · Currently, the analyst consensus on Greenwich LifeSciences is a Moderate Buy with an average price target of $38.00. See Insiders’ Hot Stocks on TipRanks >> GLSI market cap is currently $168.7M ... お米作り 課題